WS
MDGL icon

Wedbush Securities’s Madrigal Pharmaceuticals MDGL Stock Holding History

Wedbush Securities’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,286
Closed -$11K – 815
2016
Q1 		$11K Buy
+1,286
New +$10.7K ﹤0.01% 745

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Wedbush Securities's MDGL Position: Q2 2016 in Review

Wedbush Securities sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2016, closing a stake of 1,286 shares — an estimated $11K sold.

Wedbush Securities first reported a position in MDGL in Q1 2016 and held it in 1 quarter. The position peaked at $11K in Q1 2016. 55 funds tracked by Wall St. Rank hold MDGL as of Q2 2016.

  • Wedbush Securities reported no remaining Madrigal Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Wedbush Securities sold 1,286 Madrigal Pharmaceuticals shares in Q2 2016, an estimated $11K.
  • Wedbush Securities first reported a position in Madrigal Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Wedbush Securities's Madrigal Pharmaceuticals position peaked at $11K in Q1 2016.
  • 55 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2016.

Based on Wedbush Securities's 13F filing for Q2 2016, filed 2 Aug 2016.